XenoGesis Ltd. specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modelling & simulation for human PK and dose prediction. The core XenoGesis team has a proven track record of delivery in drug discovery.
Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.
The organisation combines its state-of-the-art in vitro, in vivo and bioanalytical capabilities with its expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services. Their laboratory tests demonstrate how the human body might affect the way a drug behaves, backed-up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’, which are what make the XenoGesis service attractive to global drug companies.
XenoGesis is a laboratory-based contract research organisation (CRO) based at BioCity in Nottingham and its Founder and Managing Director is Dr Richard Weaver. In 2018, XenoGesis opened a satellite office in Alderley Park and moved its head office into the state-of-the-art Discovery Building at BioCity in Nottingham.
Phone: 0115 837 0626